

Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB

2cureX AB ("2cureX") has entered into an agreement with Svensk Kapitalmarknadsgranskning AB ("SKMG") regarding Certified Adviser services. SKMG will be appointed as Certified Adviser on the 1st of July 2019. Until the 1st of July 2019, Sedermera Fondkommission will continue to act as Certified Adviser for the company.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Phone: +45 22 11 53 99
www.2curex.com

Certified Adviser

Sedermera Fondkommission
E-mail: ca@sedermera.se
Phone: +46 40 615 14 15

Certified Adviser (starting on the 1st of July 2019)

Svensk Kapitalmarknadsgranskning AB
Phone: +46 (0) 70 755 95 51
E-mail: ca@skmg.se

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient's tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol "2CUREX").